Detection of infectious organisms in archival prostate cancer tissues

BMC Cancer

Melissa A Yow⁶  Sepehr N Tabrizi⁴  Gianluca Severi⁵  Damien M Bolton³  John Pedersen¹  Anthony Longano²  Suzanne M Garland⁴  Melissa C Southey⁶  Graham G Giles⁵ 

[1] TissuPath, Mount Waverley, VIC 3049, Australia

[2] Department of Anatomical Pathology, Monash Medical Centre, Clayton, VIC 3168, Australia

[3] Department of Surgery, University of Melbourne, Austin Health, Heidelberg, VIC 3084, Australia

[4] Department of Obstetrics and Gynaecology, University of Melbourne, Melbourne, VIC 3010, Australia

[5] Centre for Epidemiology and Biostatistics, School of Population Health, University of Melbourne, Melbourne, VIC 3010, Australia

[6] Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne, Melbourne, VIC 3010, Australia

关键词: qPCR;    Infection;    Sexually transmitted infection;    Prostate cancer;   

Others  :  1125221
DOI  :  10.1186/1471-2407-14-579

 received in 2014-04-17, accepted in 2014-07-30,  发布年份 2014

【 摘 要 】

Background

Seroepidemiological studies have reported associations between exposure to sexually transmitted organisms and prostate cancer risk. This study sought DNA evidence of candidate organisms in archival prostate cancer tissues with the aim of assessing if a subset of these cancers show any association with common genital infections.

Methods

221 archival paraffin-embedded tissue blocks representing 128 histopathologically confirmed prostate cancers comprising 52 “aggressive” (Gleason score ≥ 7) and 76 “non-aggressive” (Gleason score ≤ 6) TURP or radical prostatectomy specimens were examined, as well as unaffected adjacent tissue when available. Representative tissue sections were subjected to DNA extraction, quality tested and screened by PCR for HSV-1, HSV-2, XMRV, BKV, HPV, Chlamydia trachomatis, Ureaplasma parvum, Ureaplasma urealyticum, Mycoplasma genitalium, and Trichomonas vaginalis.

Results

195 of 221 DNA samples representing 49 “aggressive” and 66 “non-aggressive” prostate cancer cases were suitable for analysis after DNA quality assessment. Overall, 12.2% (6/49) aggressive and 7.6% (5/66) non-aggressive cases were positive for any of the candidate organisms. Mycoplasma genitalium DNA was detected in 4/66 non-aggressive, 5/49 aggressive cancers and in one cancer-unaffected adjacent tissue block of an aggressive case. Ureaplasma urealyticum DNA was detected in 0/66 non-aggressive and 1/49 aggressive cancers and HSV DNA in 1/66 non-aggressive and 0/49 aggressive cancers. This study did not detect BKV, XMRV, T. vaginalis, U. parvum, C. trachomatis or HPV DNA.

Conclusions

The low prevalence of detectable microbial DNA makes it unlikely that persistent infection by the selected candidate microorganisms contribute to prostate cancer risk, regardless of tumour phenotype.

【 授权许可】

   
2014 Yow et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Ravich A, Ravich RA: Prophylaxis of cancer of the prostate, penis, and cervix by circumcision. N Y State J Med 1951, 51:1519-1520.
• [2]Taylor ML, Mainous AG, Wells BJ: Prostate cancer and sexually transmitted diseases: a meta-analysis. Fam Med 2005, 37:506-512.
• [3]Sutcliffe S, Giovannucci E, Alderete JF, Chang T-H, Gaydos CA, Zenilman JM, De Marzo AM, Willett WC, Platz EA: Plasma antibodies against Trichomonas vaginalis and subsequent risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2006, 15:939-945.
• [4]Sutcliffe S, Giovannucci E, Gaydos CA, Viscidi RP, Jenkins FJ, Zenilman JM, Jacobson LP, De Marzo AM, Willett WC, Platz EA: Plasma antibodies against Chlamydia trachomatis, human papillomavirus, and human herpesvirus type 8 in relation to prostate cancer: a prospective study. Cancer Epidemiol Biomarkers Prev 2007, 16:1573-1580.
• [5]Panguluri RCK, Long LO, Chen W, Wang S, Coulibaly A, Ukoli F, Jackson A, Weinrich S, Ahaghotu C, Isaacs W, Kittles RA: COX-2 gene promoter haplotypes and prostate cancer risk. Carcinogenesis 2004, 25:961-966.
• [6]Meyer MS, Penney KL, Stark JR, Schumacher FR, Sesso HD, Loda M, Fiorentino M, Finn S, Flavin RJ, Kurth T, Price AL, Giovannucci EL, Fall K, Stampfer MJ, Ma J, Mucci LA: Genetic variation in RNASEL associated with prostate cancer risk and progression. Carcinogenesis 2010, 31:1597-1603.
• [7]Chen Y-C, Giovannucci E, Lazarus R, Kraft P, Ketkar S, Hunter DJ: Sequence variants of Toll-like receptor 4 and susceptibility to prostate cancer. Cancer Res 2005, 65:11771-11778.
• [8]Kirnbauer R, Hubbert NL, Wheeler CM, Becker TM, Lowy DR, Schiller JT: A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16. J Natl Cancer Inst 1994, 86:494-499.
• [9]Dillner J: The serological response to papillomaviruses. Semin Cancer Biol 1999, 9:423-430.
• [10]Platz EA, De Marzo AM, Giovannucci E: Prostate cancer association studies: pitfalls and solutions to cancer misclassification in the PSA era. J Cell Biochem 2004, 91:553-571.
• [11]Giles GG, English DR: The Melbourne collaborative cohort study. IARC Sci Publ 2002, 156:69-70.
• [12]Giles GG, Severi G, McCredie MR, English DR, Johnson W, Hopper JL, Boyle P: Smoking and prostate cancer: findings from an Australian case–control study. Ann Oncol 2001, 12:761-765.
• [13]MacInnis RJ, Severi G, Baglietto L, Dowty JG, Jenkins MA, Southey MC, Hopper JL, Giles GG: Population-based estimate of prostate cancer risk for carriers of the HOXB13 missense mutation G84E. PLoS One 2013, 8:e54727.
• [14]Gleason DF: Histologic grading of prostate cancer: a perspective. Hum Pathol 1992, 23:273-279.
• [15]Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GWK, Ferris DG, Steben M, Bryan J, Taddeo FJ, Railkar R, Esser MT, Sings HL, Nelson M, Boslego J, Sattler C, Barr E, Koutsky LA, Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I Investigators: Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007, 356:1928-1943.
• [16]Resnick RM, Cornelissen MT, Wright DK, Eichinger GH, Fox HS, Scheggetter J, Manos MM: Detection and typing of human papillomavirus in archival cervical cancer specimens by DNA amplification with consensus primers. J Natl Cancer Inst 1990, 82:1477-1484.
• [17]Tabrizi SN, Stevens MP, Khan ZA, Chow C, Devitt MA, Garland SM: Comparison of PapType to Digene Hybrid Capture 2, Roche linear array, and Amplicor for detection of high-risk human papillomavirus genotypes in women with previous abnormal pap smears. J Clin Microbiol 2012, 50:2796-2798.
• [18]Mallard K, Schopfer K, Bodmer T: Development of real-time PCR for the differential detection and quantification of Ureaplasma urealyticum and Ureaplasma parvum. J Microbiol Methods 2005, 60:13-19.
• [19]Jensen JS, Björnelius E, Dohn B, Lidbrink P: Use of TaqMan 5′ nuclease real-time PCR for quantitative detection of Mycoplasma genitalium DNA in males with and without urethritis who were attendees at a sexually transmitted disease clinic. J Clin Microbiol 2004, 42:683-692.
• [20]Riley DE, Roberts MC, Takayama T, Krieger JN: Development of a polymerase chain reaction-based diagnosis of Trichomonas vaginalis. J Clin Microbiol 1992, 30:465-472.
• [21]Tabrizi SN, Paterson B, Fairley CK, Bowden FJ, Garland SM: A self-administered technique for the detection of sexually transmitted diseases in remote communities. J Infect Dis 1997, 176:289-292.
• [22]Schlaberg R, Choe DJ, Brown KR, Thaker HM, Singh IR: XMRV is present in malignant prostatic epithelium and is associated with prostate cancer, especially high-grade tumors. Proc Natl Acad Sci U S A 2009, 106:16351-16356.
• [23]Hirsch HH, Mohaupt M, Klimkait T: Prospective monitoring of BK virus load after discontinuing sirolimus treatment in a renal transplant patient with BK virus nephropathy. J Infect Dis 2001, 184:1494-1495. author reply 1495–6
• [24]Powell KF, Anderson NE, Frith RW, Croxson MC: Non-invasive diagnosis of herpes simplex encephalitis. Lancet 1990, 335:357-358.
• [25]Bergh J, Marklund I, Gustavsson C, Wiklund F, Grönberg H, Allard A, Alexeyev O, Elgh F: No link between viral findings in the prostate and subsequent cancer development. Br J Cancer 2007, 96:137-139.
• [26]Martinez-Fierro ML, Leach RJ, Gomez-Guerra LS, Garza-Guajardo R, Johnson-Pais T, Beuten J, Morales-Rodriguez IB, Hernandez-Ordoñez MA, Calderon-Cardenas G, Ortiz-Lopez R, Rivas-Estilla AM, Ancer-Rodriguez J, Rojas-Martinez A: Identification of viral infections in the prostate and evaluation of their association with cancer. BMC Cancer 2010, 10:326.